Akebia Therapeutics (STU:AX9) Short-Term Debt: €10.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AX9 Akebia Therapeutics Inc STU:AX9
51 GF Score
Price €1.20
GF Value €1.11
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Short-Term Debt?

Akebia Therapeutics STU:AX9 -1.19% 51 Short-Term Debt is €10.8 Mil as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.11 (Fairly Valued). The stock has 5 warning signs investors should review.

Akebia Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2026 was €10.8 Mil.

Akebia Therapeutics's quarterly Short-Term Debt stayed the same from Sep. 2025 (€0.0 Mil) to Dec. 2025 (€0.0 Mil) but then increased from Dec. 2025 (€0.0 Mil) to Mar. 2026 (€10.8 Mil).

Akebia Therapeutics's annual Short-Term Debt declined from Dec. 2023 (€16.0 Mil) to Dec. 2024 (€0.0 Mil) but then stayed the same from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€0.0 Mil).

Akebia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Akebia Therapeutics Short-Term Debt Related Terms

Akebia Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Short-Term Debt Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.33 30.21 16.05 0.00 0.00

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 10.81
STU:AX9
51GF Score
Akebia Therapeutics Inc STU:AX9
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €10.8 Mil mean?
Akebia Therapeutics (STU:AX9) has a Short-Term Debt of €10.8 Mil as of Mar. 2026.
Is Akebia Therapeutics' Short-Term Debt too high?
Akebia Therapeutics' current Short-Term Debt is €10.8 Mil. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Short-Term Debt compare to TKNO and ORGO?
Akebia Therapeutics' Short-Term Debt of €10.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Akebia Therapeutics's current Short-Term Debt is €10.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.11, compared to a current price of €1.20 — trading 8.2% above its estimated fair value. The current Short-Term Debt is €10.8 Mil. Akebia Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Short-Term Debt is €10.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.20 is trading 8.2% above its estimated GF Value™ of €1.11. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Short-Term Debt: €10.8 Mil
  • GF Value™: €1.11 vs. price of €1.20 (8.2% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score

Get the complete analysis for STU:AX9

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.20
Price
€1.11
GF Value